The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index; 16 of the 76 sources its claims cite were checked for support.
Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies
Open accessAbstract
Physiologically based pharmacokinetic modelling is well established in the pharmaceutical industry and is accepted by regulatory agencies for the prediction of drug-drug interactions. However, physiologically based pharmacokinetic modelling is valuable to address a much wider range of pharmaceutical applications, and new regulatory impact is expected as its full power is leveraged. As one example, physiologically based pharmacokinetic modelling is already routinely used during drug discovery for in-vitro to in-vivo translation and pharmacokinetic modelling in preclinical species, and this leads to the application of verified models for first-in-human pharmacokinetic predictions. A consistent cross-industry strategy in this application area would increase confidence in the approach and facilitate further learning. With this in mind, this article aims to enhance a previously published first-in-human physiologically based pharmacokinetic model-building strategy. Based on the experience of scientists from multiple companies participating in the GastroPlus™ User Group Steering Committee, new Absorption, Distribution, Metabolism and Excretion knowledge is integrated and decision trees proposed for each essential component of a first-in-human prediction. We have reviewed many relevant scientific publications to identify new findings and highlight gaps that need to be addressed. Finally, four industry case studies for more challenging compounds illustrate and highlight key components of the strategy.
Overview
CoChat Summary
TL;DR
This review updates a previously published first-in-human (FIH) physiologically based pharmacokinetic (PBPK) model-building strategy by integrating new ADME knowledge, QSPR inputs, decision trees, and uncertainty analysis. Four challenging industry/literature case studies illustrate how measured inputs, preclinical verification, and parameter sensitivity analysis affect FIH predictions.
Key findings
- The updated strategy emphasizes linking QSPR predictions with PBPK models before experimentation, using decision trees for elimination, distribution, oral absorption, and gut wall metabolism, and treating uncertainty/variability as central to FIH dose projection.
- Compound 1 (neutral, clogP > 5, Fu < 0.1%, aqueous solubility < 1 µg/mL) used empirical rat-derived scaling factors; predicted human hepatic clearance was 0.5 mL/min/kg (range 0.2–0.7), observed systemic clearance was 0.18 mL/min/kg, predicted Vss was 3.2 L/kg versus observed 3.7 L/kg, and observed half-life was 10–14 days versus expected ~3 days.
- Compound 2 showed blood/plasma ratio (BPR) as a critical input for a basic compound: predicted Vss was 3 L/kg with BPR = 0.91, 0.27 L/kg with BPR = 0.55, and 13.1 L/kg with BPR = 2; Vss was predicted within 60% of observed in all species except monkey (~3-fold error), and human Vss was ~20% overestimated.
- Compound 3 (lipophilic weak acid) had human clearance predicted at 0.86–4.6 mL/min/kg and Vss explored from 0.48 to 3.6 L/kg; Compound 4 (high molecular weight > 1000 Da, BCS Class III, renal) used a rat-fitted specific PStc of 9.15 × 10⁻⁵ mL/s/mL cell volume, predicting urinary elimination of 69% within 24 h and 83% within 72 h versus observed 85% and 91%.
Methods
- Design: a review and strategy update based on a comprehensive literature review and the combined experience of PBPK specialists from the GastroPlus User Group Steering Committee.
- Data/sample: four case studies—Compounds 1–3 from industry predictions and Compound 4 based on literature data—selected to illustrate challenging compounds and key strategy components.
- Analysis: simulations used GastroPlus and ADMETPredictor; the strategy incorporates QSPR plus PBPK assessment, ADME decision trees, preclinical model verification, parameter sensitivity analysis (PSA), and uncertainty/variability evaluation.
Limitations
- Stated: the paper notes that a PhRMA evaluation did not find high PBPK prediction accuracy, especially for oral administration, but argues that analysis had severe limitations including diverse in-vitro assays, a bespoke platform, and no preclinical verification; it also cites OrBiTo findings that predictive performance declines with each layer of complexity and that uncertainty is higher for modellers with < 5 years’ experience.
- Stated: several methodology gaps remain, including predicting clearance when transporters are involved, extrahepatic metabolism, enterohepatic circulation translation, improved Vss prediction when protein binding is too high to measure, validation of predicted tissue concentrations with transporters, and verification of intestinal metabolism for non-CYP3A4 gut enzymes.
- Evident: the case studies are selected challenging examples rather than a systematic validation set, and some model adjustments are empirical or not yet fully established, such as BPR adjustment for phospholipid binding/lysosomal trapping, specific PStc prediction, and reliance on preclinical verification when IVIVE fails.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
15 Valid · 5 Not valid · 36 Not checked · 116 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“For hepatobiliary clearance, it was recently demonstrated that data from sandwich-cultured hepatocytes and a consistent IVIVE approach could predict in humans for 17 diverse drugs [44].”
What the sources say
- Supportedcites [44] Kimoto E, Bi YA, Kosa RE, Tremaine LM, Varma MVS. Hepatobiliary clearance prediction: species scaling from monkey, dog, and rat, and in vitro-in vivo extrapolation of sandwich-cultured human hepatocytes using 17 drugs. J Pharm Sci. 2017;106(9):2795–804. source
The Prediction of Human Hepatobiliary Clearance Using SCHH section reports evaluating 17 compounds and obtaining good predictions from sandwich-cultured human hepatocyte data. The IVIVE calculation differed by uptake behavior: direct scaling worked for compounds without significant active uptake, while an extended clearance model with a scaling factor improved predictions for those with active uptake. Page numbers are unavailable in our copy. (LLM, conf=0.90)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It has also emerged that monkeys are a valuable model for the verification of hepatic disposition for transported molecules [44] particularly for substrates of the organic anion transporting polypeptide transporter [35].”
What the sources say
- Partly supportedcites [44] Kimoto E, Bi YA, Kosa RE, Tremaine LM, Varma MVS. Hepatobiliary clearance prediction: species scaling from monkey, dog, and rat, and in vitro-in vivo extrapolation of sandwich-cultured human hepatocytes using 17 drugs. J Pharm Sci. 2017;106(9):2795–804. sourceExperimental — accuracy not yet measured
The Discussion reports reasonable concordance between monkey and human hepatobiliary handling, and the Conclusions say monkey models show potential for predicting human hepatobiliary clearance. The source cautions that its monkey dataset is limited, so calling monkeys an established valuable model for verification is stronger than its conclusion. The OATP-specific clause is attached to a different citation [35] and is not assessed here. (LLM, conf=0.84)
- Supportedcites [35] De Bruyn T, Ufuk A, Cantrill C, Kosa RE, Bi YA, Niosi M, et al. Predicting human clearance of organic anion transporting polypeptide substrates using cynomolgus monkey: in vitro-in vivo scaling of hepatic uptake clearance. Drug Metab Dispos. 2018;46(7):989–1000. source
The Discussion concludes that cynomolgus monkeys are a valuable preclinical model for investigating hepatic uptake of OATP substrates. This directly supports the OATP-specific part of the sentence attributed to this source; the passages provide section labels but no page numbers. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The involvement of active uptake in hepatic clearance can be flagged by the Extended Clearance Classification System, and in such cases measurements in hepatocyte models may be useful [34] and human clearance predictions may be improved with cross-species empirical scaling factors [35].”
What the sources say
- Supportedcites [35] De Bruyn T, Ufuk A, Cantrill C, Kosa RE, Bi YA, Niosi M, et al. Predicting human clearance of organic anion transporting polypeptide substrates using cynomolgus monkey: in vitro-in vivo scaling of hepatic uptake clearance. Drug Metab Dispos. 2018;46(7):989–1000. source
The Prediction of Cynomolgus Monkey and Human In Vivo Clearance section reports that a cross-species empirical scaling factor reduced bias and improved precision in human predictions for the nine drugs studied. The Discussion likewise says monkey-derived scaling factors improved overall human predictions, while noting mixed results for individual drugs. This supports the citing sentence’s qualified claim that such factors may improve predictions when active uptake is involved. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A PSA can be used to determine the implications of key uncertainties [10], whether owing to limited data, lack of mechanistic understanding, inability to predict saturation of metabolism or absorption mechanisms, or a disconnect between in-vitro and in-vivo data.”
What the sources say
- Supportedcites [10] Shebley M, Sandhu P, Emami Riedmaier A, Jamei M, Narayanan R, Patel A, et al. Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective. Clin Pharmacol Ther. 2018;104(1):88–110. source
The “Sensitivity analysis” subsection under Platform Qualification says sensitivity analysis assesses how uncertainty in parameters or modeling assumptions affects simulation outcomes. The “Role of sensitivity analysis in drug model verification” section likewise recommends it for parameters with high uncertainty or high impact on predictions. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The adjustment of BPR to account for phospholipid binding as well as lysosomal trapping of basic lipophilic compounds is currently an empirical fit and exploits the observation that acidic phospholipid content is highest in tissues with high lysosomal volumes [53].”
What the sources say
- Partly supportedcites [53] Samant TS, Lukacova V, Schmidt S. Development and qualification of physiologically based pharmacokinetic models for drugs with atypical distribution behavior: a desipramine case study. CPT Pharmacometrics Syst Pharmacol. 2017;6(5):315–21. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says the increased B/P ratio served as a hybrid surrogate for phospholipid binding and lysosomal trapping, and that phospholipid content is highest in tissues with high lysosomal volumes. The Results (page unavailable) describe optimizing that ratio to fit desipramine’s observed distribution. The paper supports an empirical adjustment for desipramine, but does not establish it as the current approach for basic lipophilic compounds generally. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
85 more claims · 2 with their cited sources checked
Create a free account to see all 172 claims and to verify the 4 references still open.
- It may state two separate claims as one. 55
- Probably not a substantial claim. 38
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Miller et al. [23] further showed that integrating such single-species clearance predictions with PBPK models can enhance FIH prediction accuracy for challenging compounds.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The integration of allometric priors with PBPK mechanistic refinement represents the current state of the art for interspecies translation, provided that these limitations are acknowledged and addressed during model qualification [12,23,84].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The weight of evidence supports a disciplined, mechanism-anchored approach to interspecies extrapolation that integrates multiple methodologies rather than relying on a single technique [6,22,23,86].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [23]
Citations
Cites
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,926
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232 · cited 2×
“Scaling of in-vitro data to predict clearance should account for differences in binding in-vitro and in-vivo [70].”
BackgroundRodgers, T., & Rowland, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20502 · Cited by 946
Rodgers, T., Leahy, D., & Rowland, M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20322 · Cited by 776
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Predicting the Impact of Physiological and Biochemical Processes on Oral Drug Bioavailability
Agoram, B., Woltosz, W. S., & Bolger, M. B. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00179-x · Cited by 651
Poulin, P., & Theil, F. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10005 · Cited by 568 · cited 2×
“A PBPK model with all perfusion-limited tissues (Kp values calculated with Poulin-extracellular method, equation 4 in [69]) reasonably simulated the plasma concentrations and matched the low Vss.”
MethodJones, H., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S., Snoeys, J., Upreti, V., Zheng, M., & Hall, S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.37 · Cited by 488
Self-citation
Research works printed but not linked: 2
- Teorell T. Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration. Arch Int Pharmacodyn Ther. 1937;57:205–25.
- Nakashima M, Katagiri K, Oguma T. Phase I studies on vancomycin hydrochloride for injection. Chemotherapy. 1992;40(2):210–24.
Cited by
Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S., & Vale, N. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030332 · Cited by 390
“…which often require extensive trial-and-error adjustments to find optimal dosages [154,155], these methods accelerate this process, reducing costs and risks, and can be used in early drug development stages to predict PK parameters, facilitating decision-making and dose selection [156,157].”
BackgroundLin, W., Chen, Y., Unadkat, J. D., Zhang, X., Wu, D., & Heimbach, T. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03274-2 · Cited by 137
“Once the base PBPK model is constructed, it can predict drug PK in FIH study and consequently, be extrapolated for a number of projections, e.g., DDI, OI, and pediatrics.”
MethodInfluentialSudsakorn, S., Bahadduri, P. M., Fretland, J., & Lu, C. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200620210522 · Cited by 135
Harnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121
Rovida, C., Barton-Maclaren, T., Benfenati, E., Caloni, F., Chandrasekera, P. C., Chesné, C., Cronin, M. T. D., Knecht, J. D., Dietrich, D. R., Escher, S. E., et al. (2020) · ALTEX · doi:10.14573/altex.1912181 · Cited by 122
“To cope with the lack of experimental data, chemoinformatics may help to provide a prediction of metabolism products (Madden and Cronin, 2006; Kirchmair et al., 2015; Djoumbou-Feunang et al., 2019; Miller et al., 2019).”
Background
Metadata
- Authors
- Miller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- Array BioPharma (United States) (US)
- F. Hoffmann-La Roche AG (CH)
- Corresponding author
- Miller, Neil A.
- Venue
- Clinical Pharmacokinetics
- Published
- 2019-02-07
- Volume
- 58
- Issue
- 6
- Pages
- 727-746
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- OpenAlex
- W2912877386
- Semantic Scholar
- 6024b49d5245cd74aa54ee9087de8ed8c666758b
- Cited by
- 142
- References
- 88
- Citations by year
- 2026: 17 · 2025: 17 · 2024: 16 · 2023: 10 · 2022: 25 · 2021: 31 · 2020: 18 · 2019: 8
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- physiologically based pharmacokinetic modelling, model building strategy, ADME, in vitro to in vivo translation, drug-drug interactions, GastroPlus, decision tree, industry case studies
- MeSH terms
- Computer Simulation, Drug Industry, Pharmaceutical Preparations, Humans, Metabolic Clearance Rate, Models, Biological, Pharmacokinetics, Tissue Distribution, Quantitative Structure-Activity Relationship, Drug Discovery, Absorption, Physiological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies. https://app.cochat.ai/papers/10.1007/s40262-019-00741-9
- The paper
- Miller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N. (2019). Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-019-00741-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.